Related Experiment Video

Updated: Oct 9, 2026

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale
07:35

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale

Published on: July 8, 2025

Topiramate in the treatment of severe myoclonic epilepsy in infancy

M Nieto-Barrera1, R Candau, M Nieto-Jimenez

  • 1Paediatric Neurology Unit, Hospital Infantil Universitario Virgen del Rocio, Sevilla, Spain.

Seizure
|February 13, 2001
PubMed

Insights

Topiramate (TPM) effectively reduces seizures in severe myoclonic epilepsy in infancy (SME). Many patients experienced significant seizure reduction, with some becoming seizure-free, though side effects were noted with rapid titration.

Area of Science:

  • Pediatric Neurology
  • Epileptology
  • Pharmacology

Background:

  • Severe myoclonic epilepsy in infancy (SME) is a rare and severe form of epilepsy.
  • Current treatment options for SME have limitations, necessitating exploration of adjunctive therapies.

Purpose of the Study:

  • To evaluate the efficacy of topiramate (TPM) as an add-on treatment for reducing seizure frequency in patients with SME.
  • To assess the safety and tolerability of TPM in this patient population.

Main Methods:

  • A cohort of 18 patients diagnosed with SME was evaluated.
  • Topiramate was administered as an add-on therapy, with doses titrated gradually.
  • Seizure frequency, type, and adverse events were systematically recorded over a mean observation period of 10.5 months.

Main Results:

  • Three patients (16.6%) achieved complete seizure freedom.
  • Ten patients (55.6%) experienced a greater than 50% reduction in seizure frequency.
  • Nine patients reported side effects, predominantly mild and transient, with a higher incidence in those with weekly dose titration.

Conclusions:

  • Topiramate demonstrates significant effectiveness as an adjunctive therapy for managing severe myoclonic epilepsy in infancy.
  • Gradual dose titration is recommended to minimize adverse events, which are generally mild and transient.
  • TPM offers a promising therapeutic option for improving seizure control in SME patients.

More Related Videos

Non-restraining EEG Radiotelemetry: Epidural and Deep Intracerebral Stereotaxic EEG Electrode Placement06:58

Non-restraining EEG Radiotelemetry: Epidural and Deep Intracerebral Stereotaxic EEG Electrode Placement

Published on: June 25, 2016

Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy10:22

Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy

Published on: December 6, 2016

Related Concept Videos

Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...